American Urological Association Annual Meeting | Conference

ARAFOR Data Reveal Favorable Safety, Tolerability With Long-Term Darolutamide Exposure in mCRPC

May 14th 2022

Darolutamide was found to have a favorable safety and tolerability profile in patients with metastatic castration-resistant prostate cancer who were enrolled to the phase 1 ARAFOR study and received extended treatment with the agent for more than 4 years.

Dr. Markowski on the Efficacy of Sabizabulin in Prostate Cancer

May 14th 2022

Mark C. Markowski, MD, PhD, discusses the safety and efficacy of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.

Dr. Khetrapal on Intracorporeal Robotic vs Open Cystectomy in MIBC

May 14th 2022

Pramit Khetrapal, MD, discusses the results of evaluating intracorporeal robotic vs open cystectomy in a multicenter, randomized trial in patients with muscle-invasive bladder cancer.

Niraparib Plus Abiraterone Acetate/Prednisone Achieves Responses in HRR Gene–Altered mCRPC

May 14th 2022

The addition of niraparib to abiraterone acetate and prednisone achieved for promising response rates in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had progressed on prior treatment with an androgen receptor–targeted therapy.

Nivolumab Offers Long-Term DFS Benefits in Urothelial Carcinoma

May 14th 2022

According to longer follow-up data from the phase 3 CheckMate 274 trial, patients with high-risk, muscle-invasive urothelial carcinoma continued to experience clinically meaningful improvements in disease-free survival when treated with adjuvant nivolumab vs placebo.

18F-rhPSMA-7.3 Increases Upstaging of Disease in Recurrent Prostate Cancer

May 13th 2022

PET/CT scans conducted with 18F-rhPSMA-7.3 frequently resulted in post-scan disease upstaging compared with baseline conventional imaging in patients with prostate cancer recurrence.

Dr. Fleming on the Rationale of the SPOTLIGHT Trial in Prostate Cancer

May 13th 2022

Mark T. Fleming, MD, discusses the rationale and results from the phase 3 SPOTLIGHT trial in prostate cancer.

N-803 Plus BCG Produces Clinically Meaningful Benefit in BCG-Unresponsive Bladder Cancer

May 13th 2022

The addition of the IL15RaFc superagonist N-803 to Bacillus Calmette–Guérin led to prolonged complete responses and disease-free survival (DFS) in patients with BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ and papillary histology, respectively.

Immune-Related Adverse Effects Linked to Longer Survival With Pembrolizumab in Metastatic Urothelial Carcinoma

May 13th 2022

Patients with metastatic urothelial carcinoma who received pembrolizumab achieved prolonged median progression-free and overall survival after experiencing an immune-related adverse effect.

CDK Inhibition May Overcome Mechanisms of Olaparib Resistance in Prostate Cancer

September 15th 2021

By studying olaparib-sensitive and -resistant cell lines, researchers were able to gather insights regarding PARP inhibitor treatment and resistance mechanisms, including the use of CDK inhibition as a potential means of overcoming PARP inhibitor resistance in prostate cancer.

Olaparib Maintains Benefit Over Enzalutamide or Abiraterone in mCRPC

September 14th 2021

Olaparib was still found to produce greater clinical benefit than enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer when the novel hormonal agents were examined separately rather than combined.

Adjuvant Pembrolizumab Continues to Uphold DFS Benefit Across RCC Subgroups

September 14th 2021

Pembrolizumab as an adjuvant therapy compared with placebo continued to showcase an impressive disease-free survival benefit in patients with clear cell renal cell carcinoma following nephrectomy, with improvement observed across subgroups.

LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach

September 14th 2021

Large surface area microparticle docetaxel administered via direct intramural injection and intravesical instillations was found to be safe and showed preliminary signs of efficacy in patients with high-risk non-muscle invasive bladder cancer.

Dr. Choueiri on the Results of the KEYNOTE-564 Study in RCC

September 13th 2021

Toni K. Choueiri, MD, discusses the results of the KEYNOTE-564 study in renal cell carcinoma.

Dr. Chamie on Examining N-803 Plus BCG in BCG-Unresponsive NMIBC CIS

September 13th 2021

Karim Chamie, MD, discusses the design of the phase 2/3 QUILT-3.032 trial in patients with Bacillus Calmette-Guerín–unresponsive, non–muscle invasive bladder cancer carcinoma in situ.

Dr. Shore on the Results of the ENACT Trial in Prostate Cancer

September 13th 2021

Neal D. Shore, MD, FACS, discusses the results of the randomized, open label, phase 2 ENACT trial in prostate cancer.

UGN-101 Induction Produces Durable Responses in Low-Grade Upper Tract Urothelial Carcinoma

September 13th 2021

Treatment with the mitomycin-containing reverse thermal gel UGN-101 resulted in a lengthy period of durable response when administered as induction treatment in patients with low-grade upper tract urothelial carcinoma.

Yoga Possesses Potential to Improve QoL, Immune Responses, and Inflammation in Prostate Cancer

September 13th 2021

Improvements in quality of life, antitumor immune responses, and inflammation could be resulting benefits of the incorporation of regular yoga practice in the lives of men with prostate cancer who are undergoing prostatectomy.

MRgFUS Improved Sexual Function, Urinary Continence in Men with Intermediate-Risk Prostate Cancer

September 13th 2021

Magnetic resonance-guided focused ultrasound focal therapy delivered to the index lesion produced better outcomes for men with intermediate-risk prostate cancer compared with radical prostatectomy or radiation therapy.

18F-DCFPyL Could Become a Key Diagnostic Tool for Biochemical Recurrence in Prostate Cancer

September 13th 2021

18F-DCFPyL, a PET prostate specific membrane antigen targeting agent, demonstrated statistically significant potential in detecting biochemical recurrence in men with prostate cancer.

x